Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs T-Mobile Us Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while T-Mobile Us Inc trades at $188.76 (market cap $203.03B). The key difference: T-Mobile Us Inc is far larger — about 5.1× Alnylam Pharmaceuticals, Inc.'s market cap, and T-Mobile Us Inc pays a 2.17% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TMUS | |
|---|---|---|
Market Cap | $39.89B | $203.03B |
Sector | Health | Media |
52-Week High | $491.22 | $259.01 |
52-Week Low | $278.09 | $167.65 |
Enterprise Value | $38.15B | $320.73B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
T-Mobile US (TMUS) trades at $187.61, up 3.38% on the day, with a neutral technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $88.31B, net income of $10.99B, and consistent cash flow generation. Recent leadership changes and competitive threats from SpaceX's potential market entry are key developments. Valuation metrics include a P/E of 19.94 and P/S of 2.32, while the consensus price target is $244.50, suggesting significant upside potential.
The outlook for TMUS is positive due to strong earnings beats, healthy profitability margins, and growth in postpaid accounts. Risks include rising debt levels, intense competition, and capital expenditure pressures. With 83% of analysts rating it a Buy, the stock presents a compelling opportunity for long-term investors, though monitoring competitive dynamics and interest expense trends is crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
